Russian pharmaceutical industry aims to develop the vaccines manufacturing

| By | Vaccine Production, Vaccines
0
1996

Russian pharmaceutical forum held in St. Petersburg discussed the major issues faced by the market of vaccines and immunobiological medicines. Victor Dmitriev, the CEO of Association of Russian Pharmaceutical Manufacturers (ARPM), noted the importance and relevance of these products.

“The vaccines and immunobiological medicines make a strong impact on national biosecurity, incidence of infectious diseases and, of course, no vital activity is actually possible in today’s world without them. As a result, we set clear and, at the same time, ambitious targets to develop the manufacturing of vaccines, establish more transparent and civilized market environment so that the commercial non-state enterprises become at least cost-effective, or better yet profitable,” he said.

Vladimir Khristenko, the President of Nanolek, spoke about the important role of vaccines in the public health care system.

“Currently, there is no problem with the sale or overproduction of vaccines. At this time, the world is facing the shortage of vaccines. The production facilities are not adequately meeting the needs of states and non-government organizations in the area of vaccination. It would be rather difficult to move forward without collaborating with consumers and limited number of manufacturers involved in the production of vaccines on the global scale, and without forming a real alliance. This also applies to Russia,” said Vladimir Khristenko.

He compared the statistics on 2016 costs of vaccines in Russia and Italy. With 1.9 million newborns in Russia in 2016, the per capita cost of vaccination amounted to 5260 rubles, and the costs of vaccine procurement for the National Immunization Calendar stood at 10 billion rubles. At the same time, in Italy, with 500 thousand newborns, the cost of vaccination was 36,000 rubles, and the costs of vaccine procurement for the National Immunization Calendar reached 18 billion rubles.